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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.11.003PURPOSE: Sorafenib is considered a standard of care in advanced hepatocellular carcinoma (HCC). Its combi-
nation with gemcitabine, a pyrimidine analogue with limited friendly hepatic profile may prove beneficial in
advanced HCC. The primary objective was to evaluate the efficacy and safety of a sorafenib and gemcitabine
combination in patients with advanced HCC.
METHODS: This was a non-randomized, open-label, single-arm, multi-centric Phase II study conducted in
Pakistan where 30 treatment-naive patients aged between 26 and 73 years with Child–Pugh score A or B were
treated with sorafenib (400 mg oral) twice daily for 16 weeks along with gemcitabine (1000 mg/m2 intravenous)
administered on day 1 and day 8 of a four-week cycle for 16 weeks.
RESULTS: Of the 18 patients (60%) who completed all four cycles of treatment, eight patients had stable dis-
ease, two had partial response, and eight had progressive disease. There was no complete response. The most
common (10% patients) treatment-emergent adverse events were gemcitabine-related thrombocytopenia
(40%) followed by sorafenib-related hand–foot skin reaction and anorexia (33% each).
CONCLUSION: The efficacy of sorafenib gemcitabine combination therapy is similar to the sorafenib alone
treatment. However, frequent dose adjustments due to gemcitabine-related toxicities, delays, and corrective
treatments make this combination therapy unsafe in the treatment of advanced HCC.Hepatocellular carcinoma (HCC) is the ﬁfthleading cause of cancer death worldwide,and the majority of patients are Asians
[1,2]. Treatment options for HCC depend on the
stage of the disease, co-existing cirrhosis, and the
patient’s overall condition. While in early stage of
cancer, surgical resection or liver transplantation
may be curative; however, only about 15% of patients
have resectable disease at presentation. The majority
of patients present in the advanced disease stage,
and hence are considered candidates for non surgical
options. Until the late 1990s, there was no worldwide,
approved local or systemic therapy for advanced HCC
and all available therapies for advanced unresectable
and metastatic HCC had limited clinical value,
with low response rates, and little impact on theHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comnatural history of the disease [3]. It was for the
ﬁrst time that in 2008 a large Phase III trial
established the survival beneﬁt of sorafenib in
advanced HCC [4]. However, the results remain
humble with overall survival beneﬁt of around four
months. The need for improvement was therefore
well recognized.
HCC is considered to have intrinsic resistance to
chemotherapy agents. This is due to increased expres-
sion of multidrug resistance transporters and active
intracellular metabolism [5]. A large number of
controlled and uncontrolled studies performed with
different classes of chemotherapeutic agents have
yielded low response rates [6–8] After the success
of sorafenib, combination regimens with chemothera-
peutic agents came under investigation [9].27
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Most HCCs develop in cirrhotic livers with im-
paired liver function and therefore drug hepatic
metabolism and its toxicity in this setting is important
while considering any therapeutic trial [10]. Gemcita-
bine, a pyrimidine analogue, is metabolized intracellu-
larly by nucleoside kinases, and excreted mainly in
urine. Earlier studies with gemcitabine in patients
with liver impairment and elevated aspartate amino-
transferase (AST 2-times the upper limit of normal
[ULN]) did not show any increase in toxic effects re-
lated to gemcitabine. However, dose reduction was
recommended in patients with elevated bilirubin levels
(>27 lmol/L) [11] This established a limited hepatic
friendly proﬁle of gemcitabine in HCC and the
hypothesis was that its combination with sorafenib
may be beneﬁcial. Thus, the primary objective of this
Phase II study was to evaluate the efﬁcacy and safety
of a sorafenib and gemcitabine combination therapy in
patients with advanced HCC.METHODS
Study population
Adult treatment-naïve patients of either sex with
advanced HCC were enrolled. Eligible patients were
with Child–Pugh score A or B, an Eastern
Cooperative Oncology Group (ECOG) Performance
Status of 0 or 1 along with bidimensionally measur-
able (as per World Health Organization guidelines)
and histologically proven unresectable tumors.
Child–Pugh B patients were included based on simi-
lar pharmacokinetics reported for sorafenib in both A
and B stage patients by Abou-Alfa et al. in the Journal
of Clinical Oncology in 2005. Additional inclusion
criteria included adequate liver function (bilirubin
<1.5 · ULN; alanine aminotransferase and AST
<2.5 · ULN; alkaline phosphatase <4 · ULN;
prothrombin time <1.5 · ULN), adequate renal
function (serum creatinine <1.5 · ULN), adequate
bone marrow (hemoglobin >10 g/dL; absolute
neutrophil count >1500/mm3; platelet count
>100 · 1000 cells/lL), and life expectancy of at least
12 weeks. Patients treated with anticoagulants (coum-
adin or heparin) earlier were allowed to participate,
provided there was no abnormality in these parame-
ters at screening.
Patients were excluded if they had uncontrolled
hypertension, clinically active serious infection
(>Grade 2 as per National Cancer Institute-
Common Terminology Criteria v3.0), extra-hepatic
metastasis, or history of bleeding diathesis. Pregnant
or breastfeeding females, patients with seizureHedisorder requiring medication (such as steroids or
anti-epileptics), patients undergoing renal dialysis,
and patients requiring trans-arterial catheter emboli-
zation were excluded from the study.
The Independent Ethics Committee or Institu-
tional Review Board at each study site approved the
protocol and the study was conducted in accordance
with the ethical principles outlined in the Declaration
of Helsinki and in accordance with ICH Good Clin-
ical Practice guidelines, applicable regulatory require-
ments, and in compliance with the respective protocol.
All patients provided written informed consent.
Study design
This was a 16-week, non-randomized, open-label, sin-
gle arm, multi-centric, Phase II study conducted in
Pakistan from 1st September 2008 to 30th December
2009.
Safety and toxicity evaluations were completed at
baseline and on days 1 and 8 of each cycle before
the administration of gemcitabine or at the time of
early withdrawal. Interim analysis for efﬁcacy was per-
formed at 8 weeks (after two cycles) and on comple-
tion of the 4th cycle.
Study medication
Patients were treated with sorafenib 400 mg oral
twice daily for 16 weeks along with gemcitabine
1000 mg/m2, intravenous, administered on days 1
and 8 of a four-week cycle for 16 weeks. At 16 weeks
an evaluation was required and patents having stable
disease, complete or partial remission were continued
on treatment combination until any reason for study
withdrawal. Gemcitabine dose reduction of 20% was
allowed in patients with underlying cirrhosis liver hav-
ing increased bilirubin, but not exceeding 27 lmol/L.
As the potential dose limiting toxicity for gemcitabine
is myelosuppression, its dose reduction by 20% was
further allowed in case of clinically signiﬁcant toxici-
ties (National Cancer Institute-Common Terminol-
ogy Criteria v3.0) and in case of dose delays due to
toxicities for more than seven days.
Study withdrawal
All patients were required to complete four cycles un-
less there was disease progression, consent with-
drawal, or clinically signiﬁcant toxicities for more
than seven days despite corrective measures. Neutro-
phil growth factors for primary prophylaxis were not
allowed except in secondary settings when there were
delays due to persisting Grade 2 neutropenia or more,
for more than seven days, and on occurrence of amatol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
Table 1. Demographics and baseline characteristics of intent- to-treat
population.
Parameter Values





Child–Pugh stagea, n (%)
A 24 (80%)
B 6 (20%)
ECOG performance statusb, n (%)
0 15 (50%)
1 15 (50%)
Alpha fetoprotein levels, n (%)
Normal/insignificant (500 IU) 8 (27%)




Hepatitis C, n (%)
Positive 20 (67%)
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single febrile neutropenic episode. Re-escalation of the
study drug was permitted with appropriate prophy-
laxis in patients who had completely resolved adverse
event. Dose modiﬁcation for sorafenib was not al-
lowed in the absence of any known sorafenib-related
toxicities with the exception of thrombocytopenia
for which the gemcitabine dose would be modiﬁed
ﬁrst. The treatment was discontinued in case of
sorafenib-related Grade 3 or 4 toxicities.
Efﬁcacy assessment
The primary efﬁcacy assessment was tumor response
which was done in accordance with the Response
Evaluation Criteria for Solid Tumors (RECIST
1.0). The investigator performed the tumor measure-
ments at baseline and at 8 weeks or two cycles (inter-
im analysis). For a patient to be regarded as achieving
stable disease, a 16-week of documented non-pro-
gression was required.
Safety assessment
All drug-related adverse events were analyzed accord-
ing to National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events (NCI-CTCAE)
Version 3.0, and all serious adverse events regardless
of causal relationship to study drugs were recorded.
Statistical analysis
The data was analyzed using Statistical Package for
the Social Sciences (SPSS) computer program. Chi-
square test was applied to examine any signiﬁcant
association between tumor response and other cate-
gorical variables (Child class, ECOG status, Alpha
fetoprotein levels, uni/multicentricity). A p value
of < 0.05 was considered signiﬁcant.Hepatitis B, n (%)
Positive 4 (13%)
No viral evidence 6 (20%)
Cirrhotic liver 30 (100%)
BCLCc stage C 30 (100%)
BCLC, barcelona clinic liver cancer classification; ECOG, eastern cooperative oncology group;
SD, standard deviation.
aThe Child–Pugh system evaluates the severity of liver disease, with patients divided into
classes from A to C, with class C representing the worst prognosis.bThe ECOG performance
status assesses the daily living abilities of the patient, on a scale ranging from 0 (fully active)
to 5 (dead).
cThe BCLC system ranks hepatocellular carcinoma in five stages, ranging from 0 (very early
stage) to D (terminal stage).RESULTS
Demographics
The study enrolled 30 Asian patients aged between 26
and 73 years (both ages inclusive) (median age:
55.3 years); the majority were men (77%). Baseline
demographics and disease characteristics are shown
in Table 1. Overall, 18 (60%) patients completed all
four cycles of treatment; four patients expired, two
of whom had gastrointestinal hemorrhage from
esophageal varices, and the other two had disease-
related decline in liver function and hepatic failure.
Of the eight patients who were withdrawn from
the study, two had progressive disease at interim
evaluation on eight-week treatment, and six (33%)
had persisting gemcitabine-related Grade 3/4 throm-
bocytopenia despite corrective measures (includingHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comdose adjustments and dose delay for more than
1 week).29
Table 3. Incidence of drug-related adverse events (safety population,
n = 30).
Adverse event Grade 1=2 n (%) Grade 3=4 n (%) Total
n (%)
Neutropenia 4 (13) 0 (0) 4 (13)
Anemia 6 (20) 2 (7) 8 (27)
Thrombocytopenia 4 (13) 6 (20) 10 (33)
Deteriorating liver function 4 (13) 2 (7) 6 (20)
Diarrhea 2 (7) 4 (13) 6 (20)
Hand–foot skin reaction 10 (33) 0 10 (33)
Anorexia 10 (33) 0 10 (33)
Fatigue 4 (13) 0 4 (13)
Vomiting 3 (10) 0 3 (10)
Epistaxis 2 (7) 0 2 (7)
Alopecia 3 (10) 0 3 (10)
Hypertension 2 (7) 0 2 (7)
Listed are adverse events, as defined by the National Cancer Institute Common Terminology
Criteria (version 3.0).
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Among 18 patients, eight (44%) patients achieved sta-
ble disease while two (11%) patients showed partial re-
sponse. No complete response was observed (Table 2).
There was no signiﬁcant association found
between tumor response and any of the variables:
Child–Pugh score (p = 0.260), ECOG performance
(p = 0.264), AFP levels (p = 0.64) and uni/multicen-
tricity (p = 0.712).
Safety
The most common (10% patients) treatment-emer-
gent adverse events (TEAEs) were hematological
events; gemcitabine-related thrombocytopenia was
most common (40%) TEAE and required frequent
dose modiﬁcations and delays. Six patients were with-
drawn from the study due to persisting thrombocyto-
penia of Grade 2 despite corrective treatment and
dose delay for more than seven days. Dose modiﬁca-
tions (reduction by 20% of calculated gemcitabine
dose) due to thrombocytopenia alone were common:
two on the average in all patients who completed all
eight doses (four cycles). All patients experienced delay
in dose at least once up to seven days due to persisting
thrombocytopenia. Blood transfusion was required as
corrective measure for anemia in two patients, and
platelet transfusion was required in four patients for
persisting Grade 3–4 thrombocytopenia. Hand-foot
skin reaction (33%) and anorexia (33%) were the most
common adverse events due to sorafenib (Table 3).
DISCUSSION
In the present study, of the 60% patients who
completed all four cycles of treatment, 11% had
partial response while 44% had stable disease, and
the remaining 44% had progressive disease. In con-
trast, the SHARP trial conducted earlier with sorafe-Table 2. Summary of efficacy measures.
Sorafenib + Gemcitabine treatment
Total assessed, n (%) 18 (60)
Level of response, n (%)
Complete response 0 (0)
Partial response 2 (11)
Stable disease 8 (44)
Progressive disease 8 (44)
Note: The level of response was measured according to RECIST (Response Evaluation Criteria
in Solid Tumors) by independent radiologic review.
Henib alone showed 71% of patients with stable disease at
the end of the treatment period [4] This may be be-
cause of the difference in the baseline characteristics
between the two populations. The Asian population
enrolled in the present study was much younger (mean
age: 55 years) compared with the population in the
SHARP study (mean age: 64 years) [12] The popula-
tion in our study was similar to the Asia–Paciﬁc pop-
ulation studied by Cheng et al. (mean age: 51 years).
The tumor load, ECOG status, and Child–Pugh sta-
tus in our study population were also similar to the
study by Cheng et al. [13]. compared with the baseline
population characteristics of the SHARP trial [12]
The study by Cheng et al., which had patients with ad-
vanced HCC and treated with sorafenib alone – in line
with the SHARP study – resulted in 54% of patients
with stable disease [13], which is similar to our ﬁnd-
ings. Thus, in terms of tumor response, no improve-
ment was observed with the combination of
sorafenib and gemcitabine in the present study com-
pared to the sorafenib treatment as seen in the
Asia–Paciﬁc (Cheng et al.) and the SHARP studies.
Serum AFP response has been related to the pre-
diction of radiological response and survival as an
independent prognostic factor [14] There was no rela-
tion between tumor response and baseline AFP level
in this study.matol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
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Most of the TEAEs related to sorafenib observed
in this study (hand-foot skin reaction, diarrhea and
anorexia) are similar to the adverse effects reported
in earlier studies [12,13] The gemcitabine-related
hematological toxicities observed in the present study
are also seen in earlier reported studies. Earlier studies
with gemcitabine in HCC, used as single agent [15] or
in combination with cisplatin or doxorubicin, have
shown similar toxicity [16] However, there were fre-
quent dose adjustments, and delays during the treat-
ment due to gemcitabine-related hematological
toxicities for almost all the patients at least once in
the 16-week treatment. In addition to this, corrective
treatments like blood transfusion (two patients) and
platelet transfusion (four patients) were needed dur-
ing the treatment.
Eric Assenat et al. presented the GONEXT study
from France in the 2013 meeting of the American
Society of Clinical Oncology. Sorafenib plus gemcita-
bine and oxliplatin (twice weekly) was found to be fea-
sible although subset analysis as to who beneﬁtted
most is awaited. Hematological toxicity was common
but was not the limiting factor in this study. In our
study, all patients had cirrhosis liver: 80% of those
with Child–Pugh score A.
The limitation was that this was a non-random-
ized study, and only 60% of patients were evaluable.Hematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comGemcitabine alone administered in the same dose
but on day 1 and day 8 of a four-weekly cycle plus
sorafenib was found to be hematologically more toxic.CONCLUSION
There is no difference between the efﬁcacy of sorafe-
nib and gemcitabine combination therapy and sorafe-
nib alone treatment. However, higher gemcitabine-
related toxicity followed by frequent dose adjust-
ments, delays, and corrective treatment including
blood component therapy makes this combination
therapy unsuitable for the treatment of advanced
HCC.
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